Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?
During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requirement of the EMA and FDA and statistical considerations.
They touched upon:
- Primary endpoints in ALS clinical trials
- Regulatory requirements: differences between EMA and FDA
- Statistical considerations for ALSFRS-R, survival and composites
Followed by a Q&A session.
Speakers: Prof. Leonard van den Berg, MD, PhD & Dr. Ruben van Eijk, MD, PhD
Related webinars
Webinar: Real-World Data in ALS
On 30 May, we hosted the webinar "Real-World Data in ALS", in which we explored the innovative integration of Real World Data (RWD) in clinical trials for Amyotrophic Lateral Sclerosis (ALS). As a critical step forward in the pursuit of effective ...
Webinar: Selecting and successfully integrating cognitive testing into clinical trials
On May 9, we presented the webinar: Selecting and successfully integrating cognitive testing into clinical trials During this webinar, hosted by Dr. Lieza Exalto, speaker Dr. John Harrison discussed: Cognitive domains – which ones sho...
Measuring and tracking everyday functioning in AD clinical trials with the Amsterdam IADL Questionnaire
In collaboration with our partner Brain Research Center, we presented the webinar: Measuring and tracking everyday functioning in AD clinical trials with the Amsterdam IADL Questionnaire Speakers: Dr. Sietske Sikkes | Associate Professor a...